[go: up one dir, main page]

MX2017007000A - Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. - Google Patents

Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.

Info

Publication number
MX2017007000A
MX2017007000A MX2017007000A MX2017007000A MX2017007000A MX 2017007000 A MX2017007000 A MX 2017007000A MX 2017007000 A MX2017007000 A MX 2017007000A MX 2017007000 A MX2017007000 A MX 2017007000A MX 2017007000 A MX2017007000 A MX 2017007000A
Authority
MX
Mexico
Prior art keywords
hepe
methods
compositions
treating
same
Prior art date
Application number
MX2017007000A
Other languages
English (en)
Other versions
MX382116B (es
Inventor
Rowe Jonathan
Duffy Kevin
Climax John
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MX2017007000A publication Critical patent/MX2017007000A/es
Publication of MX382116B publication Critical patent/MX382116B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona composiciones que comprenden 15-HEPE, y métodos para utilizar las mismas para el tratamiento y/o prevención de la fibrosis en un sujeto en necesidad de las mismas.
MX2017007000A 2014-12-02 2015-12-02 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. MX382116B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
PCT/US2015/063488 WO2016090030A1 (en) 2014-12-02 2015-12-02 Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (2)

Publication Number Publication Date
MX2017007000A true MX2017007000A (es) 2017-12-07
MX382116B MX382116B (es) 2025-03-13

Family

ID=56092410

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007000A MX382116B (es) 2014-12-02 2015-12-02 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2021005080A MX2021005080A (es) 2014-12-02 2017-05-29 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021005080A MX2021005080A (es) 2014-12-02 2017-05-29 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.

Country Status (17)

Country Link
US (1) US10363235B2 (es)
EP (2) EP3226873B1 (es)
JP (2) JP6986445B2 (es)
KR (1) KR20170102879A (es)
CN (2) CN112245419A (es)
AU (2) AU2015358512B2 (es)
BR (1) BR112017011685A2 (es)
CA (1) CA2968980A1 (es)
ES (1) ES2900593T3 (es)
IL (2) IL252431B (es)
MA (1) MA41120A (es)
MX (2) MX382116B (es)
PH (1) PH12017501022B1 (es)
RU (2) RU2020115523A (es)
SG (2) SG11201704495VA (es)
WO (1) WO2016090030A1 (es)
ZA (2) ZA201704463B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
MX2016008953A (es) * 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
JP2018502163A (ja) * 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU2634101A (en) * 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
EP3285072B1 (en) * 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JPWO2009154230A1 (ja) 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
MX2014004710A (es) 2011-10-19 2014-12-10 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos.
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
US20150057216A1 (en) * 2011-12-16 2015-02-26 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法

Also Published As

Publication number Publication date
ZA201804380B (en) 2021-03-31
EP3226873A1 (en) 2017-10-11
JP2017536380A (ja) 2017-12-07
CA2968980A1 (en) 2016-06-09
ES2900593T3 (es) 2022-03-17
ZA201704463B (en) 2018-11-28
HK1245101A1 (zh) 2018-08-24
RU2017122758A (ru) 2019-01-09
PH12017501022A1 (en) 2017-11-27
JP2022031813A (ja) 2022-02-22
SG10202010594WA (en) 2020-12-30
MX2021005080A (es) 2021-06-15
CN107206008A (zh) 2017-09-26
AU2015358512B2 (en) 2021-02-18
BR112017011685A2 (pt) 2018-01-02
WO2016090030A1 (en) 2016-06-09
JP6986445B2 (ja) 2021-12-22
RU2017122758A3 (es) 2019-06-13
SG11201704495VA (en) 2017-06-29
EP3988101A1 (en) 2022-04-27
RU2020115523A (ru) 2021-01-27
RU2721555C2 (ru) 2020-05-20
AU2015358512A1 (en) 2017-07-20
US10363235B2 (en) 2019-07-30
IL252431B (en) 2021-12-01
EP3226873A4 (en) 2018-08-08
IL252431A0 (en) 2017-07-31
PH12017501022B1 (en) 2022-02-16
IL287983A (en) 2022-01-01
AU2021203189A1 (en) 2021-06-10
EP3226873B1 (en) 2021-10-27
US20160184252A1 (en) 2016-06-30
MX382116B (es) 2025-03-13
MA41120A (fr) 2017-10-10
KR20170102879A (ko) 2017-09-12
CN112245419A (zh) 2021-01-22

Similar Documents

Publication Publication Date Title
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
EA201790380A1 (ru) Ингибиторы mk2 и их применения
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
HUE054204T2 (hu) Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
ZA201705561B (en) Kv1.3 inhibitors and their medical application
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
PH12017500602A1 (en) Methods for treating ocular conditions
PH12017501864A1 (en) Compositions and methods for treating autism
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12016501838A1 (en) Compounds and their methods of use
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.
ZA201705676B (en) Kv1.3 inhibitors and their medical application